optinose.com - OPTN Company profit before taxes, interest and amortization
OptiNose, Inc. (OPTN) specializes in developing nasal devices for sinusitis therapy, targeting the growing demand from ENT patients. The EBITDA financial metric confirms the development trajectory, where the indicator determines the magnitude of the metric. However, slow sales and marketing expenses are limiting margins. Business stability is ensured by Xsail patents and FDA approval, which create significant barriers to entry for competitors.
Summary analytical data breakdowns for OptiNose (OPTN)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio OptiNose, Inc.|OPTN - Long-Term Debt to Equity|Current Liabilities to Capital OptiNose Inc|OPTN - Company Debts|Debts to Book Capitalization Ratio OptiNose|OPTN - Company Long-Term Liabilities|Amount of Current Liabilities OptiNose|Interim Coverage Ratio optinose.com
- earnings and market ratios statistics:
OPTN - Company Net Income|Net Profit Forecast OptiNose, Inc.|OPTN - Price to Earnings Ratio|Projected Price to Earnings Ratio optinose.com|OPTN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio OptiNose|OPTN - Operating profit EBITDA|Net earnings per one share for the last twelve months OptiNose|OPTN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months optinose.com|OPTN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year OptiNose, Inc.
Analysis of all company metrics:OptiNose Corp, OPTN
The sale of specialized Xhance nasal sprays directly generates cash flow, which is reflected in the absolute EBITDA. This indicator aggregates daily receipts from core operations, allowing investors to differentiate periods of stagnation from expansion phases, which, combined with the optimization of commercial expenses, confirms the resilience of the current OptiNose, Inc. business model.
Competitor analysis for OptiNose, Inc.
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Galapagos GLPG|ANI Pharmaceuticals Inc (ANIP) - Profit before interest, taxes and amortization|MNKD - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization AMPH|PCRX (Pacira BioSciences) - Operating profit before deduction of amortization|SPRY: Company profit before taxes, interest and amortization|TBPH (Theravance Biopharma, Inc.) - Operating profit EBITDA|Aquestive Therapeutics Inc (AQST) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization scPharmaceuticals Inc. (SCPH)|tectonictx.com - Operating profit before amortization|Profit before payment of interest, taxes and amortization Tonix Pharmaceuticals TNXP|SXT Pharmaceuticals (SXTC) - Profit before interest, taxes and amortization|EPRX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization BioHarvest Sciences, Inc. BHST|EXOZ: Operating profit EBITDA|Profit before interest, taxes and amortization Oramed Pharmaceuticals Inc. (ORMP)|Operating profit before deduction of amortization ENTX|HYFT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ABVC|Operating income before deduction of amortization Cumberland Pharmaceuticals Inc|Profit before payment of interest, taxes and amortization Quantum BioPharma Limited QNTM|FGEN: Operating profit before amortization|Telomir Pharmaceuticals - Operating profit EBITDA|Rani Therapeutics (RANI) - Operating profit before deduction of amortization|SNYR (synergychc.com) - Operating profit before deduction of amortization|RLYB - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Lexaria Bioscience Corp|Profit before interest, taxes and amortization Pulmatrix Corporation PULM|Profit before payment of interest, taxes and amortization Pheton Holdings Ltd (PTHL)|APM: Profit before deduction of interest, taxes, depreciation and amortization|Lyra Therapeutics - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization IBO (Impact BioMedical, Inc.)|TNFA - Profit before payment of interest, taxes and amortization|YCBD (cbdMD, Inc.) - Operating profit before amortization|PainReform Ltd. (PRFX) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization CYTO (Altamira Therapeutics Ltd.)|LIPO (Lipella Pharmaceuticals, Inc.) - Operating profit EBITDA|PIRS: Income before deduction of interest, taxes and amortization|Operating profit EBITDA PROC|Operating profit EBITDA Petros Pharma (PTPI)|Profit before payment of interest, taxes and amortization Qilian International QLI|Income before deduction of interest, taxes and amortization SLRN|TFFP - Profit before payment of interest, taxes and amortization
